Main Article Content
Abstract
Etodolac is commonlyused moderate pain, fever, and inflammation.The project was designed with an aim to develop and evaluate sustainedrelease Etodolac tabletwhich will reduce the dosing frequency and have better patient complianceand less fluctuations in plasma concentration. The matrix tablets were prepared by the direct compression method.The prepared sustained release tabletswere evaluated for angle of repose, bulk density, tapped density, Carr’s index, Hausner’s ratio at the precompression stage and thickness, weight variation, hardness, friability, drug content, in vitro drug release study at the post compression stage. In vitro dissolution studies (USP dissolution ratetest apparatus II, 50 rpm, 37°C ± 0.5°C) was carried out for the first 2 h in 0.1 N HCl (1.2 pH) and followed6.8 phosphate buffer for 12 h as a dissolution medium. The optimized formulation F-4 was shownmaximum drug release 98.31 in 12 h of dissolution. The release kinetic data of formulation F-4 shown Peppas release kinetics. FT-IR studies revealed that there was no interaction between the drug and polymers.